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proportion was signiﬁcantly higher in males than females
(25.7% vs. 20.0%, p < 0.001). Overall mean age was
45.84 (IP 46.64; OP 45.62, p < 0.001). Proportion of 
IP among all LCs was signiﬁcantly higher among older
people (18–34y: 20.4%; 35–44y: 19.9%; 45–54y:
20.2%; 55–65y: 24.7%, p < 0.001). IP proportions by
diagnosis were: calculus of the gall bladder and/or bile
duct, 31.8%; other gall bladder disorders (including
cholecystitis), 13.9%; diseases of the pancreas, 87.6%;
and all other diagnoses, 41.3% (p < 0.001). Mean net
cost for LC hospital admission was $9168 (95% CI:
$8913–$9424) and average LOS was 3.6 days (95% CI:
3.4–3.8). Net OP procedure cost for LC was $3158 (95%
CI: $3123–$3194). CONCLUSIONS: Nearly 80% of
LCs in the US managed care population were ambulatory-
based. Patients undergoing IP LC were signiﬁcantly dif-
ferent from patients undergoing OP LC in age, gender,
and primary diagnosis. Cost of hospital-based LC was
almost three times higher than cost of ambulatory-based
LC.
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OBJECTIVE: Several medications are equally efﬁcacious
regardless of dosage form. This study conducted a cost-
minimization analysis from an institutional perspective 
of a pharmacist-directed intravenous to oral conversion
program for pantoprazole, a proton pump inhibitor (PPI).
Empirical evidence supports equivalence of IV and tablet
forms of pantoprazole in inhibiting gastric acid secretion.
METHODS: Patients on IV pantoprazole in select units
at a tertiary care teaching hospital between March 15,
2002 and April 12, 2002 were included in the interven-
tion group. Following a protocol approved by the Phar-
macy & Therapeutics Committee, a pharmacist evaluated
patients to determine eligibility for conversion to admin-
istration by mouth or nasogastric tube. The pharmacist
recorded times required to identify and switch patients.
Average times required for preparation, dispensing, and
administration of dosage forms were determined via
employee interview. Medication acquisition and labor
costs were obtained from the hospital ﬁnancial depart-
ment. Proportion of days therapy with each dosage form
for the intervention group and historical control group,
which otherwise met identical inclusion criteria, were
determined from the pharmacy database. RESULTS: A
signiﬁcant difference in proportion of days therapy with
PPI dosage forms existed between control (N = 182) and
intervention (N = 150) groups (C2 = 276.39, df = 2, p <
0.05). The intervention increased total proportion of days
therapy with pantoprazole tablets and PPI suspensions by
6.9% and 22.0%, respectively. Days therapy with IV 
pantoprazole were decreased by 28.8% (from 61.2% to
32.4%). Applying costs for medications, supplies, and
labor, the conversion program saves $13.45/patient
started on IV pantoprazole. Projecting cost saving to 1
year with 1887 patients/year, the conversion program
could save $25,380.15 in the hospital budget. CON-
CLUSION: A pharmacist-directed intravenous to oral
dosage form conversion program can result in institu-
tional cost savings. However, cost savings are dependent
on success in converting patients. Cost savings would 
be increased to $18.50/patient on IV pantoprazole by
shifting an additional 6.9% of PPI therapy days from IV
pantoprazole to pantoprazole tablets.
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OBJECTIVE: To compare the epidemiology and treat-
ment of GERD and nocturnal GERD in a U.S. national
sample of elderly (65+ years of age) and younger adults
(<65 years of age). METHODS: A national random-
sample phone survey of 9035 adults identiﬁed 171 elderly
and 1090 younger adults with symptomatic GERD, and
42 elderly and 329 younger adults with nocturnal GERD.
Symptomatic GERD cases reported heartburn or regurgi-
tation 1+ time/week in past three months. Nocturnal
GERD was deﬁned as symptomatic GERD with 1+
nocturnal symptom 1+ time/week. Severe was deﬁned as
2+ episodes/week. The interview included questions on
symptom frequency, concomitant motility-related symp-
toms, and treatment for GERD symptoms. Chi-square
tested for statistical signiﬁcance between elderly and
younger adults. RESULTS: Prevalence of symptomatic
GERD (9.9% vs. 14.9%; p < 0.0001) and nocturnal
GERD (2.4% vs. 4.5%; p < 0.0001) was lower and less
severe (74% vs. 87%; p < 0.05) in elderly than younger
adults. Most bothersome symptoms were regurgitation in
elderly, and heartburn in younger adults. Among GERD
cases, motility-related symptoms (e.g., post-prandial full-
ness, early satiety) were less prevalent or less frequent in
the elderly than younger adults. Among nocturnal GERD
cases, prevalence of motility-related symptoms was not
different between elderly and younger adults, but the
elderly reported less severe post-prandial fullness (p <
0.05) and a lower frequency of nausea (p < 0.001) than
younger adults. Prescription medication use for GERD-
related symptoms was reported by 24% of nocturnal
GERD cases and did not differ by age. However, elderly
